GSK agrees Â£9.2bn deal
British drugs giant GlaxoSmithKline has agreed a 13 billion US dollar (Â£9.2 billion) deal to buy Novartis's stake in its consumer healthcare joint venture.
Glaxo will snap up the 36.5% stake to take full ownership of the division just a week after it pulled out of the bid auction for US group Pfizer’s consumer healthcare business amid a shake-up in the sector.
The companies only launched the joint venture in 2015, but Swiss group Novartis said the deal was at an “attractive price”, while Glaxo said it would allow the group to “capture the full value” of the business.
Glaxo added it is now considering putting its malted drinks brand Horlicks up for sale as part of a review of consumer nutrition products to help fund the deal with Novartis.
The review will also include its 72.5% stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare.
These are the most annoying things you can say to somebody from Sheffield - don't mention John Lewis
Hunt to find woman responsible for sexually assaulting man at Sheffield railway station
Knife-wielding thug who stabbed four victims on a Sheffield estate faces a possible life sentence
Sheffield tram late: These Sheffield trams will only run hourly today and Saturday due to Network Rail strike
Rotherham child sex abuse: Sheffield man arrested today for alleged offences against girl, 14
Glaxo said the products under review make sales of around £550 million a year, with the bulk generated in India.
Emma Walmsley, chief executive of Glaxo, said the Novartis deal will see shareholders “capture the full value of one of the world’s leading consumer healthcare businesses”.
She added it will also help the group “accelerate efforts to improve performance”.
“Most importantly it also removes uncertainty and allows us to plan use of our capital for other priorities, especially pharmaceuticals R&D,” she said.
Newly appointed Novartis boss Vas Narasimhan, who took on the role in February, said: “While our consumer healthcare joint venture with GSK is progressing well, the time is right for Novartis to divest a non-core asset at an attractive price.”
The deal is expected to complete in the summer.